# A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

> **NCT00557596** · PHASE1,PHASE2 · TERMINATED · sponsor: **Aegera Therapeutics** · enrollment: 48 (estimated)

## Conditions studied

- Carcinoma
- Pancreas

## Interventions

- **DRUG:** AEG35156

## Key facts

- **NCT ID:** NCT00557596
- **Lead sponsor:** Aegera Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2009-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00557596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00557596, "A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00557596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*